The impact of hepatitis C burden: An evidence-based approach

Z. M. Younossi, F. Kanwal, S. Saab, K. A. Brown, H. B. El-Serag, W. R. Kim, A. Ahmed, M. Kugelmas, S. C. Gordon

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

Background Infection with the hepatitis C virus (HCV) has been considered a major cause of mortality, morbidity and resource utilisation in the US. In addition, HCV is the main cause of hepatocellular cancer (HCC) in the US. Recent developments in the diagnosis and treatment of HCV, including new recommendations pertaining to screening for HCV by the Centers for Disease Control and Prevention and newer treatment regimens with high efficacy, short duration and the potential for interferon-free therapies, have energised the health care practitioners regarding HCV management. Aim To assess the full impact of HCV burden on clinical, economic and patient-reported outcomes. Methods An expert panel was convened to assess the full impact of HCV burden on a number of important outcomes using an evidence-based approach predicated on Grading of Recommendations Assessment, Development and Evaluation methodology. The literature was summarised, graded using an evidence-based approach and presented during the workshop. Workshop presentations were intended to review recent, relevant evidence-based literature and provide graded summary statements pertaining to HCV burden on topics including the relationships between HCV and the development of important outcomes. Results The associations of HCV with cirrhosis, HCC, liver-related mortality, type 2 diabetes mellitus, rheumatological diseases and quality of life impairments are supported by strong evidence. Also, there is strong evidence that sustained viral eradication of HCV can improve important outcomes such as mortality and quality of life. Conclusions The current evidence suggests that HCV has been associated with tremendous clinical, economic and quality of life burden.

Original languageEnglish (US)
Pages (from-to)518-531
Number of pages14
JournalAlimentary Pharmacology and Therapeutics
Volume39
Issue number5
DOIs
StatePublished - Mar 2014

Fingerprint

Hepatitis C
Hepacivirus
Liver Neoplasms
Quality of Life
Mortality
Economics
Education
Virus Diseases
Centers for Disease Control and Prevention (U.S.)
Type 2 Diabetes Mellitus
Interferons
Fibrosis
Morbidity
Delivery of Health Care

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Younossi, Z. M., Kanwal, F., Saab, S., Brown, K. A., El-Serag, H. B., Kim, W. R., ... Gordon, S. C. (2014). The impact of hepatitis C burden: An evidence-based approach. Alimentary Pharmacology and Therapeutics, 39(5), 518-531. https://doi.org/10.1111/apt.12625

The impact of hepatitis C burden : An evidence-based approach. / Younossi, Z. M.; Kanwal, F.; Saab, S.; Brown, K. A.; El-Serag, H. B.; Kim, W. R.; Ahmed, A.; Kugelmas, M.; Gordon, S. C.

In: Alimentary Pharmacology and Therapeutics, Vol. 39, No. 5, 03.2014, p. 518-531.

Research output: Contribution to journalArticle

Younossi, ZM, Kanwal, F, Saab, S, Brown, KA, El-Serag, HB, Kim, WR, Ahmed, A, Kugelmas, M & Gordon, SC 2014, 'The impact of hepatitis C burden: An evidence-based approach', Alimentary Pharmacology and Therapeutics, vol. 39, no. 5, pp. 518-531. https://doi.org/10.1111/apt.12625
Younossi ZM, Kanwal F, Saab S, Brown KA, El-Serag HB, Kim WR et al. The impact of hepatitis C burden: An evidence-based approach. Alimentary Pharmacology and Therapeutics. 2014 Mar;39(5):518-531. https://doi.org/10.1111/apt.12625
Younossi, Z. M. ; Kanwal, F. ; Saab, S. ; Brown, K. A. ; El-Serag, H. B. ; Kim, W. R. ; Ahmed, A. ; Kugelmas, M. ; Gordon, S. C. / The impact of hepatitis C burden : An evidence-based approach. In: Alimentary Pharmacology and Therapeutics. 2014 ; Vol. 39, No. 5. pp. 518-531.
@article{78fd1dfdabe44830aebdb0041fc6a88e,
title = "The impact of hepatitis C burden: An evidence-based approach",
abstract = "Background Infection with the hepatitis C virus (HCV) has been considered a major cause of mortality, morbidity and resource utilisation in the US. In addition, HCV is the main cause of hepatocellular cancer (HCC) in the US. Recent developments in the diagnosis and treatment of HCV, including new recommendations pertaining to screening for HCV by the Centers for Disease Control and Prevention and newer treatment regimens with high efficacy, short duration and the potential for interferon-free therapies, have energised the health care practitioners regarding HCV management. Aim To assess the full impact of HCV burden on clinical, economic and patient-reported outcomes. Methods An expert panel was convened to assess the full impact of HCV burden on a number of important outcomes using an evidence-based approach predicated on Grading of Recommendations Assessment, Development and Evaluation methodology. The literature was summarised, graded using an evidence-based approach and presented during the workshop. Workshop presentations were intended to review recent, relevant evidence-based literature and provide graded summary statements pertaining to HCV burden on topics including the relationships between HCV and the development of important outcomes. Results The associations of HCV with cirrhosis, HCC, liver-related mortality, type 2 diabetes mellitus, rheumatological diseases and quality of life impairments are supported by strong evidence. Also, there is strong evidence that sustained viral eradication of HCV can improve important outcomes such as mortality and quality of life. Conclusions The current evidence suggests that HCV has been associated with tremendous clinical, economic and quality of life burden.",
author = "Younossi, {Z. M.} and F. Kanwal and S. Saab and Brown, {K. A.} and El-Serag, {H. B.} and Kim, {W. R.} and A. Ahmed and M. Kugelmas and Gordon, {S. C.}",
year = "2014",
month = "3",
doi = "10.1111/apt.12625",
language = "English (US)",
volume = "39",
pages = "518--531",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - The impact of hepatitis C burden

T2 - An evidence-based approach

AU - Younossi, Z. M.

AU - Kanwal, F.

AU - Saab, S.

AU - Brown, K. A.

AU - El-Serag, H. B.

AU - Kim, W. R.

AU - Ahmed, A.

AU - Kugelmas, M.

AU - Gordon, S. C.

PY - 2014/3

Y1 - 2014/3

N2 - Background Infection with the hepatitis C virus (HCV) has been considered a major cause of mortality, morbidity and resource utilisation in the US. In addition, HCV is the main cause of hepatocellular cancer (HCC) in the US. Recent developments in the diagnosis and treatment of HCV, including new recommendations pertaining to screening for HCV by the Centers for Disease Control and Prevention and newer treatment regimens with high efficacy, short duration and the potential for interferon-free therapies, have energised the health care practitioners regarding HCV management. Aim To assess the full impact of HCV burden on clinical, economic and patient-reported outcomes. Methods An expert panel was convened to assess the full impact of HCV burden on a number of important outcomes using an evidence-based approach predicated on Grading of Recommendations Assessment, Development and Evaluation methodology. The literature was summarised, graded using an evidence-based approach and presented during the workshop. Workshop presentations were intended to review recent, relevant evidence-based literature and provide graded summary statements pertaining to HCV burden on topics including the relationships between HCV and the development of important outcomes. Results The associations of HCV with cirrhosis, HCC, liver-related mortality, type 2 diabetes mellitus, rheumatological diseases and quality of life impairments are supported by strong evidence. Also, there is strong evidence that sustained viral eradication of HCV can improve important outcomes such as mortality and quality of life. Conclusions The current evidence suggests that HCV has been associated with tremendous clinical, economic and quality of life burden.

AB - Background Infection with the hepatitis C virus (HCV) has been considered a major cause of mortality, morbidity and resource utilisation in the US. In addition, HCV is the main cause of hepatocellular cancer (HCC) in the US. Recent developments in the diagnosis and treatment of HCV, including new recommendations pertaining to screening for HCV by the Centers for Disease Control and Prevention and newer treatment regimens with high efficacy, short duration and the potential for interferon-free therapies, have energised the health care practitioners regarding HCV management. Aim To assess the full impact of HCV burden on clinical, economic and patient-reported outcomes. Methods An expert panel was convened to assess the full impact of HCV burden on a number of important outcomes using an evidence-based approach predicated on Grading of Recommendations Assessment, Development and Evaluation methodology. The literature was summarised, graded using an evidence-based approach and presented during the workshop. Workshop presentations were intended to review recent, relevant evidence-based literature and provide graded summary statements pertaining to HCV burden on topics including the relationships between HCV and the development of important outcomes. Results The associations of HCV with cirrhosis, HCC, liver-related mortality, type 2 diabetes mellitus, rheumatological diseases and quality of life impairments are supported by strong evidence. Also, there is strong evidence that sustained viral eradication of HCV can improve important outcomes such as mortality and quality of life. Conclusions The current evidence suggests that HCV has been associated with tremendous clinical, economic and quality of life burden.

UR - http://www.scopus.com/inward/record.url?scp=84893810524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893810524&partnerID=8YFLogxK

U2 - 10.1111/apt.12625

DO - 10.1111/apt.12625

M3 - Article

C2 - 24461160

AN - SCOPUS:84893810524

VL - 39

SP - 518

EP - 531

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 5

ER -